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OBJECTIVE — To identify factors associated with declining -cell compensation for insulin
resistance.
RESEARCH DESIGN AND METHODS — In a cohort of Hispanic women with recent
gestationaldiabetesmellitus,oralglucosetolerancetests(OGTTs),intravenousglucosetolerance
tests (IVGTTs), and bioelectrical impedance measurements were performed at 15-month inter-
valsforupto5years,oruntilfastingplasmaglucoseexceeded140mg/dl(7.8mmol/l).Datawere
analyzed to identify predictors of declining -cell compensation for insulin resistance (the
dispositionindex[DI])andtoexaminethemechanismofweightgainandchangesincirculating
levels of selected adipokines and inﬂammatory markers on -cell compensation decline.
RESULTS — A total of 60 nondiabetic women had a median of four sets of OGTT  IVGTT
during a median follow-up of 52 months. Fourteen of the women developed diabetes. None of
thebaselinecharacteristicsweresigniﬁcantlypredictiveofadeclineinDI.Thereweresigniﬁcant
univariate associations between declining DI and weight gain (speciﬁcally fat gain), declining
adiponectin and rising C-reactive protein. Multivariate analysis showed that the weight gain was
the most signiﬁcant factor associated with declining DI. The amount of association between
weight gain and declining DI was explained 31% by changes in adiponectin and C-reactive
protein and 40% by changes in insulin resistance.
CONCLUSIONS — Theseresultsidentifyweightgainasthestrongestfactorassociatedwith
declining -cell compensation for insulin resistance in Hispanic women at high risk for type 2
diabetes.Sucheffectmaybemediatedthroughatleasttwoeffects:alterationsinadipokinelevels
and increasing insulin resistance.
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T
ype 2 diabetes is characterized by
inadequate pancreatic -cell com-
pensation for chronic insulin resis-
tance. Longitudinal studies in Pima
Indians (1), Caucasian and African Amer-
icans(2,3),andHispanicAmericans(2,4)
indicate that -cell function declines on a
background of chronic and often worsen-
ing insulin resistance as people progress
from normal to impaired glucose toler-
anceandthentodiabetes.Muchisknown
about baseline factors that predict a rela-
tivelyshorttimetodiabetes—factorssuch
as relatively high glucose levels, insulin
resistance, and poor -cell compensation
for insulin resistance. Those factors could
be important driving forces for the devel-
opment of diabetes. They could also sim-
ply be markers of individuals closest to
diabetes at the initiation of follow-up.
Much less is known about the
cause(s) of the progressive deterioration
in -cell function that leads to impaired
glucose tolerance and diabetes. Declining
-cell function has been shown to be as-
sociated with weight gain in Pima Indians
(5) and with increased fat in women with
a family history of type 2 diabetes (6).
Glucose and lipid toxicity have been sug-
gested as causes of declining -cell func-
tion (7), although data are lacking from
humanstosupportsuchaneffectoverthe
years that it takes to develop diabetes.
We conducted a longitudinal study
investigating the pathogenesis of diabetes
developmentinrelativelyyoungHispanic
women with recent gestational diabetes
mellitus. We observed a progressive de-
cline in -cell compensation for insulin
resistancethatwasattendedbyslowlyris-
ing glucose levels until -cell compensa-
tion reached very low levels, at which
time glucose levels rose to the diabetic
range (4). The present analysis examines
what baseline characteristics predict the
declinein-cellcompensationforinsulin
resistance and the potential role and
mechanism of weight gain and changes in
circulating levels of adipokines and in-
ﬂammatory markers during follow-up on
declining -cell compensation in this
high-risk group.
RESEARCH DESIGN AND
METHODS— Subjectsforthepresent
report were islet cell antibody–negative
womenwhoparticipatedinalongitudinal
study of the pathogenesis of type 2 diabe-
tes after gestational diabetes mellitus. Se-
lection of the original cohort has been
describedindetail(8,9).Brieﬂy,allLatino
women referred to Los Angeles County
Women’s Hospital for management of
gestational diabetes mellitus between Au-
gust 1993 and March 1995 were asked to
participate if they met all of the following
criteria:1)gestationalagebetween28and
34 weeks, 2) no current or prior insulin
therapy, 3) all fasting serum glucose con-
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during pregnancy, 4) otherwise uncom-
plicatedsingletonpregnancy,and5)both
parents and at least three of four grand-
parents from Mexico, Guatemala, or El
Salvador. All women had detailed meta-
bolic testing during the third trimester.
They were asked to return for a 75-g oral
glucose tolerance test (OGTT) 6 months
postpartumandthenforanOGTTandan
intravenous glucose tolerance test
(IVGTT) at 15 months postpartum and
every 15 months thereafter. Height,
weight, and information on contraceptive
use and pregnancies were collected at
each visit. Bioelectrical impedance (BIA)
wasmeasuredateachOGTTvisittoassess
body composition. At the time of diagno-
sis of impaired glucose tolerance, our di-
abetic subjects met with a dietitian and
received advice on nutrition and daily
walking. Subjects remained in follow-up
until they withdrew consent, were lost to
follow-up, or developed a fasting plasma
glucoseconcentration140mg/dl(7.8
mmol/l),atwhichtimetheywerereferred
for pharmacological treatment. Women
whowerepregnantatthetimeofasched-
uledbatteryoftestswerestudiedatleast4
months after pregnancy and at least 1
month after completion of breastfeeding.
Family history of diabetes was not as-
sessed for this cohort.
For the present report, which is fo-
cusedonnonpregnantwomenfrom15to
75 months postpartum (occurred be-
tween October 1994 and November
2001), we analyzed data from all subjects
who 1) had a baseline OGTT and IVGTT
without diabetes in the 15- or 30-month
postpartum testing window and 2) re-
turned for at least one additional set of
OGTT and IVGTT by the 75-month post-
partum test window. All subjects gave
written informed consent for participa-
tion in the study, which was approved by
the Institutional Review Board of the Uni-
versity of Southern California and the Los
Angeles County plus University of South-
ern California Medical Center.
Testing protocols
For a battery of OGTT, IVGTT, and BIA,
subjects came to the General Clinical Re-
search Center on 2 separate days, at least
48 h apart, after an 8- to 12-h overnight
fast and at least 3 days on an unrestricted
diet.
On day 1, BIA was measured imme-
diately before an OGTT between 0700
and 1000. For BIA, subjects lay supine
while plastic electrodes were placed on
their right hand and foot and a trained
technician took dual resistance and reac-
tance readings with a Quantom Imped-
ance Meter (RJL Systems, Michigan). For
OGTTs, subjects drank 75 g dextrose.
Blood was obtained from an antecubital
venouscatheterbeforeand15,30,60,90,
and 120 min after the glucose ingestion
and placed on ice, and plasma was sepa-
ratedwithin20minandstoredat80°C.
Fasting plasma samples from the OGTTs
were used later to measure free fatty acids
(FFAs), adiponectin, leptin, C-reactive
protein (CRP), and interleukin (IL)-6.
Onaseparateday,anIVGTTwasper-
formed starting between 0700 and 1000.
Dextrose(300mg/kg)wasinjectedover1
min, followed in 20 min by a 5-min infu-
sion of crystalline human insulin (0.03
units/kg). Arterialized venous blood was
drawn into iced tubes before (n  2) and
for 240 min after (n  32) the dextrose
injection.Plasmawasseparatedwithin20
min and stored at 80°C.
Laboratory analysis
Glucose was measured by a glucose oxi-
dase (Beckman Glucose Analyzer II;
Beckman Coulter, Brea, CA). Insulin was
measured by a radioimmunoassay (RIA)
(Novo Pharmaceuticals, Danbury, CT)
that measured insulin and proinsulin
with intra- and inter-observer coefﬁcient
of variations (CV) of 2.3 and 4.4%.
Plasma FFAs were measured by an enzy-
matic colorimetric method using a kit
from WAKO Chemicals (intra- and inter-
observer CVs of 0.75 and 0.37%).
Plasmaadiponectinandleptinlevelswere
measured using RIA kits from LINCO Re-
search (intra- and inter-observer CVs of
8.3 and 9.2%). Plasma CRP and IL-6
were measured using CRP ELISA (intra-
and inter-observer CVs of 6.0 and
13.8%) and ultrasensitive IL-6 ELISA kits
(intra- and inter-observer CVs of 8.3
and 10.0%) from ALPCO Diagnostics.
Data analysis
BMIwascalculatedasweightinkilograms
divided by the square of height in meters.
Diabetes was diagnosed using American
Diabetes Association criteria (10). IVGTT
resultswereanalyzedusingtheMINMOD
program (11) to obtain measures of frac-
tionalglucosedisappearanceduetoanin-
crease in insulin above basal (insulin
sensitivity [SI]).
Theacuteinsulinresponsetointrave-
nousglucose(AIRg)wascalculatedbythe
trapezoid rule as the incremental area un-
der the insulin curve during the ﬁrst 10
min after the glucose injection. The prod-
uct of SI and AIRg (the disposition index
[DI]) was calculated as a measure of acute
pancreatic -cell compensation for insu-
lin resistance (11). Body fat and fat-free
mass were calculated by the formula of
Kotleretal.(12)usingheight,weight,and
BIA measurements.
Baseline characteristics are presented
as mean (SD) and ranges (Table 1). For
data analysis, log-transformation was ap-
pliedforCRP,fastingand2-hinsulin,30-
minincrementalinsulin,SI,AIRg,andDI.
Thus, geometric means are presented for
these variables where appropriate. Rates
of change for variables that were mea-
sured at each follow-up visit (weight,
body composition, AIRg, SI, and DI) were
estimated by regressing follow-up data in
each subject against follow-up time for
that subject. Fasting FFA, adiponectin,
CRP,leptin,andIL-6weremeasuredonly
at baseline and last follow-up visit, so
their rates of change were estimated as
[last baseline]/[follow-up time] for each
subject.Fastingtotal,HDL,andLDLcho-
lesterol and triglycerides were not col-
lected during follow-up. Relationship
between follow-up changes in glucose
and DI decline has been evaluated previ-
ously (4) and was not the focus in this
report;thus,follow-upchangesonOGTT
glucose and insulin were not included in
this report. Random coefﬁcient mixed-
effect models were used to test for signif-
icant changes over time for DI, SI, AIRg,
weight, and body composition. Mixed-
effect models were also used to test for
signiﬁcant associations between changes
in the primary outcome variable, DI, and
1) baseline variables (Table 1) and 2)
changes during follow-up in pregnancy
status, use of hormonal contraception,
body weight, fat and fat-free mass, circu-
lating levels of FFA, adiponectin, CRP,
leptin and IL-6. In evaluating the predic-
tion of baseline SI, AIRg, and DI on the
primary outcome rate of change in DI, we
appliedabiascorrectiontoadjustforpos-
sible artiﬁcial negative correlation due to
measurement error, sometimes referred
to as “regression to the mean.” Measure-
menterroraccountedfor15,12,and15%
of the total variation for SI, AIRg, and DI,
respectively (estimated from 109 His-
panic women with similar characteristics
who participated in a separate study
where IVGTTs were repeated after 3
months without any treatment [13]). The
bias corrected point estimates were ob-
tained using an empirical formula devel-
oped through simulation for longitudinal
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estimates were obtained by the bootstrap
method with 100 replications. In each
bootstrap sample, 60 subjects were ran-
domly selected with replacement from
the original sample; mixed-effect models
were then ﬁtted and bias corrected esti-
mates were obtained.
All statistical tests were two-sided,
and statistical signiﬁcance was deﬁned as
P  0.05.
RESULTS
Baseline characteristics
Sixtywomenmettheinclusioncriteriafor
this report; 28 had normal glucose toler-
ance and 32 had impaired glucose toler-
ance.Atbaseline(Table1),thecohorthad
an average age of 32 years and an average
BMI and body fat consistent with obesity.
Mean glucose levels were consistent with
impaired glucose tolerance, and mean in-
sulin sensitivity was very low. However,
therewasawiderangeforallbaselineval-
ues in the cohort.
Changes during follow-up
The median duration of follow-up was 52
months. There were 25 women who had
allﬁvepossiblevisits,19hadfour,12had
three, and 4 had two. During follow-up,
14 of the women developed diabetes,
15% of the women used estrogen-
progestin combination oral contracep-
tives, and 15% used progestin-only
contraceptives; two women (3%) used
both at different times. A total of 25% of
the women experienced one or more ad-
ditionalpregnanciesduringthefollow-up
period.
During follow-up (Table 1), mean
weight increased signiﬁcantly (0.75 
1.18 kg/year; P  0.0001), although
some women gained and some lost
weight. Body fat also increased signiﬁ-
cantly(0.561.01kg/year;P0.0001),
and changes in body fat accounted for
75% of the changes in body weight. Fast-
ing FFA and leptin increased signiﬁcantly
(P  0.001) and adiponectin decreased
signiﬁcantly (P  0.01). There were no
signiﬁcant changes across the cohort in
CRP, IL-6, or SI. AIRg and DI both fell
signiﬁcantly(P0.001).Figure1depicts
mean values for weight, DI, SI, and AIRg
at each follow-up time.
Factors associated with the decline
in -cell compensation
Univariate analysis with random coefﬁ-
cients mixed-effect modeling revealed
that none of the baseline characteristics
listed in Table 1 except baseline AIRg and
DI were signiﬁcantly associated with rate
of change in DI during follow-up (P 
0.15 for each). Baseline AIRg and DI were
signiﬁcantly negatively associated with
rate of change in DI (regression coefﬁ-
cient  SE  0.031  0.0107 log DI
unitperyear/logAIRgunit,P0.004,for
baseline AIRg; 0.0337  0.0103 log DI
unit per year/log DI unit for baseline DI,
P  0.0014, respectively). After correct-
ing for potential bias due to regression to
the mean, baseline AIRg and DI were no
longersigniﬁcantlyassociatedwithrateof
change in DI (regression coefﬁcients were
reducedto0.00560.0123logDIunit
peryear/logAIRgunit,P0.65,forbase-
line AIRg; 0.0009  0.0096 log DI unit
per year/log DI unit for baseline DI, P 
0.92, respectively).
For follow-up characteristics, addi-
tional pregnancies, use of hormonal con-
traception, changes in FFAs, leptin, and
IL-6 were not signiﬁcantly associated
with rate of change in DI (P  0.30). Rate
of change in DI was signiﬁcantly associ-
ated with rates of change in weight
(0.026  0.007 log DI unit/kg, P 
0.0003), adiponectin (0.055  0.018 log
DI unit per ng/ml  10
3, P  0.002),
andCRP(0.1100.035logDIunitper
log ng/ml, P  0.002) univariately. The
association with CRP was noted despite
the fact that there was on average no sig-
niﬁcant change in CRP in this cohort (Ta-
Table 1—Baseline and follow-up characteristics
Mean  SD*
Range (minimum,
maximum)
Baseline
Age (years) 32.6  5.6 22.0, 42.6
BMI (kg/m
2) 30.6  4.9 18.2, 45.4
Body percent fat† 44.3  5.8 28, 57
Fasting total cholesterol (mg/dl) 173.8  30.5 114, 251
Fasting HDL cholesterol (mg/dl) 39.5  10.5 20, 74
Fasting LDL cholesterol (mg/dl) 105.9  30.7 50.2, 166.2
Fasting triglycerides (mg/dl) 136.1  71.2 43, 374
Fasting FFA (	mol/l) 500  205 265, 1,372
Adiponectin (ng/ml) 6,326  2,179 1,099, 12,002
CRP (ng/ml) 28.6  30.8 30, 233
Leptin (ng/ml) 11.8  4.5 5, 33
IL-6 (pg/ml) 2.4  1.2 0.6, 7.7
Fasting glucose (mg/dl)‡ 96.8  8.5 82, 116
2-h glucose (mg/dl)‡ 142.6  30.4 64, 194
Fasting insulin (	U/ml)‡ 17.0  9.1 3, 56
2-h insulin (	U/ml)‡ 105.5  72.3 16, 446

 Insulin at 30 min (	U/ml)§ 82.2  43.1 14, 321
Insulin sensitivity (SI, min
1 per 	U/ml  10
4)  1.44  0.46 0.5, 5.5
Acute insulin response (AIRg, 	U/ml  min)¶ 514  257 47, 4,803
DI (SI  AIRg)# 726  249 50, 2,249
Rates of change during follow-up
Weight (kg/year) 0.75  1.18‡‡ 2.4, 4.5
Body fat (kg/year)† 0.56  1.01‡‡ 2.4, 3.7
Fasting FFA (	mol/l per year) 96  138‡‡ 236, 445
Adiponectin (ng/ml per year) 211  532†† 2,327, 771
CRP (log ng/ml per year) 0.02  0.32 1.07, 1.49
Leptin (ng/ml per year) 1.34  2.18‡‡ 3.48, 8.07
IL-6 (pg/ml per year) 0.07  0.38 0.94, 1.25
SI (log unit per year) 0.02  0.14 0.48, 0.51
AIRg (log unit per year) 0.08  0.14‡‡ 0.60, 0.20
DI (log unit per year) 0.06  0.08‡‡ 0.21, 0.15
n  60. *Geometric means  SDs were presented for baseline CRP, fasting and 2-h insulin, 
insulin at 30
min,insulinsensitivity,acuteinsulinresponse,andDI.†Estimatedbybioelectricalimpedance.‡During75-g
OGTTs. §30 min minus baseline value for plasma insulin.  Calculated by minimal model analysis of IVGTT
insulin and glucose data. ¶Incremental insulin area during ﬁrst 10 min of IVGTT. #A measure of -cell
compensation for insulin resistance. Signiﬁcant changes: ††P  0.01, ‡‡P  0.001. To convert the glucose
in units of mg/dl to the SI unit of mmol/l, multiply the number in the table by 0.0555.
Weight gain and declining -cell compensation
398 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.orgble 1). Results of the multivariate analysis
withwhichweassessedthepotentialcon-
tributions of changing adiponectin and
CRP to the association between change in
DIandweightgainappearinTable2.The
univariate association between weight
gain and declining DI was reduced by
19% after adjustment for changes in ei-
theradiponectinorCRPandby31%after
adjustment for both (Table 2). Nonethe-
less, change in weight remained signiﬁ-
cantly associated with change in DI after
these adjustments (Table 2, adjusted P 
0.02).Thus,weightgainwasthestrongest
factor that associated with declining DI,
and that association was reduced but re-
mained signiﬁcant after adjustment for
changes in adiponectin and CRP.
We have previously shown that insu-
lin resistance can contribute to declining
-cell function in Hispanic women
(13,15). To determine whether the pat-
tern of association we observed between
DI, weight gain, and changing CRP and
adiponectin was simply due to insulin re-
sistance, we performed analysis with fol-
low-up SI as a covariate. Adjustment for
changes in SI alone reduced the associa-
tion between weight gain and declining
DI by 40%, but the association remained
statistically signiﬁcant (P  0.037). Add-
ing adjustment for changes in SI to the
previous 31% reduction caused by ad-
justment for adiponectin and CRP re-
sulted in a total of 70% reduction of the
relationship between weight gain and de-
clining DI. Indeed, the association be-
tween weight gain and declining DI was
no longer statistically signiﬁcant (P 
0.29). The adjustment for changes in SI
had little impact on the relationship be-
tweenfailingDIandchangesinadiponec-
tin and CRP after weight gain was
included. Thus, changes in insulin resis-
tance, adiponectin, and CRP all appeared
to contribute to the relationship between
weight gain and declining DI.
Multivariate analysis including the
two major components of weight (body
fat and fat-free mass) indicated that the
decline in DI was signiﬁcantly associated
with the gain in fat mass (P  0.01), but
not the fat-free mass (P  0.16).
CONCLUSIONS — In relatively young
and nondiabetic Hispanic women with
prior gestational diabetes mellitus, we
were unable to identify baseline charac-
teristics that were predictive of declining
-cellcompensationforinsulinresistance
over the next 5 years. By contrast, we
identiﬁed several changes that were asso-
ciated with declining DI. The strongest
was weight gain. Additional factors were
declining levels of adiponectin and rising
CRP. In multivariate analysis, approxi-
mately one-third of the association be-
tween weight gain and declining -cell
compensation was accounted for statisti-
cally by these two variables. These associ-
ations were not simply due to increasing
insulin resistance; adjustment for change
in insulin sensitivity accounted for an ad-
ditional40%oftheassociationbetween
weightgainanddeclining-cellfunction.
Onaverage,75%ofweightgainwasbody
Figure 1—Plot of mean weight, DI, SI, and ﬁrst-phase insulin secretion (AIRg) by visit month. Geometric means are shown for DI, SI, and AIRg;
arithmetic mean is shown for weight. Vertical lines are the associated 95% CIs for the means.
Table 2—Impact of changes in adiponectin and CRP on the relationship between changes in
weight and DI during follow-up
Variables adjusted
Regression coefﬁcient 
SE (log DI unit/kg)* P
% Reduction compared
with no adjustment†
None 0.026  0.007 0.0003 —
Change in adiponectin 0.021  0.007 0.006 19%
Change in CRP 0.021  0.007 0.005 19%
Changes in adiponectin and CRP 0.018  0.008 0.02 31%
*Estimated from random-coefﬁcient mixed-effect model regression analysis. †Calculated as 100  (unad-
justed regression coefﬁcient  adjusted regression coefﬁcient)/unadjusted regression coefﬁcient.
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that was associated with declining DI.
Taken together, our ﬁndings indicate that
weight gain was the strongest factor that
contributed to the decline in -cell com-
pensation for insulin resistance in His-
panic women at high risk for type 2
diabetes. Such an effect was mediated
through at least two effects: increasing in-
sulin resistance and alterations in adipo-
kine levels.
The signiﬁcant association between
declining -cell compensation and
weightgainconﬁrmedobservationsmade
previouslybyWeyeretal.inPimaIndians
(5) and by Kriketos et al. (6) in women
withafamilyhistoryoftype2diabetes.In
Weyer’s study, 209 nondiabetic Pima In-
dians (151 with normal glucose tolerance
and 58 with impaired glucose tolerance)
were evaluated an average of 2.6 years af-
terbaseline.Weightgainwassigniﬁcantly
correlated with declining DI in both nor-
mal glucose tolerance and impaired glu-
cose tolerance; the correlation was
stronger in the subgroup with impaired
glucose tolerance (5). In Kriketos’s study,
20 women with a family history of type 2
diabetes (risk group) and 15 women
withoutafamilyhistoryoftype2diabetes
(control group) were tested at baseline
and 6 years later. Insulin resistance and
secretion were assessed by homeostasis
model assessment (HOMA)-R and
HOMA-. Baseline levels and changes
over time in total and central abdomi-
nal fat mass were inversely related to
HOMA- (6). Our study provides novel
information about the potential media-
tion of declining -cell function associ-
ated with weight gain. Some may be due
to increasing insulin resistance, which is
not surprising given the beneﬁcial effects
of chronic use of insulin-sensitizing med-
ications on -cell function in this popu-
lation (13,15). Additional contributors
may be endocrine and/or inﬂammatory
productsofadiposetissue,anovelﬁnding
to our knowledge.
Epidemiological studies have re-
vealed direct associations between diabe-
tes risk and markers of inﬂammation (16)
andinverseassociationsbetweendiabetes
risk and adiponectin levels (17,18). In
vitro studies reveal evidence for detri-
mental effects of cytokines (19) and ben-
eﬁcial effects of adiponectin (20) on
-cells in the short term. The present
study demonstrated longitudinal associa-
tion between adipocyte-derived hormones
anddeclining-cellcompensationforinsu-
lin resistance in humans. The results raise
the possibility that circulating products of
adipose tissue such as adiponectin and in-
ﬂammatory cytokines are harmful to
-cells.
We did not ﬁnd evidence for an effect
of leptin, IL-6, FFA, baseline level of glu-
cose, cholesterol, triglyceride, insulin re-
sistance, insulin secretion, and -cell
compensation on changes in -cell com-
pensation in this cohort. The lack of im-
pact of initial glucose levels is consistent
with other studies we have conducted in
this high-risk group (13) and speaks
against glucotoxicity as a major cause of
declining -cell function in pre-diabetic
individuals. The lack of an effect of lipid
levels, including FFAs, speaks against li-
potoxicity, although circulating lipid lev-
elsobtainedinthefastingstatemaynotbe
a good indicator of lipid delivery to or
metabolism by -cells. The lack of an ef-
fect of initial insulin resistance, secretion,
and -cell compensation after correcting
for the bias due to measurement error did
not support the hypothesis that high in-
sulin resistance, high insulin secretion,
and-cellcompensationleadtofasterde-
clining of -cell compensation in this
high-risk, very insulin-resistant group.
We recognized that the relative small
samplesizeinthisreportlimitedourabil-
ity to identify small effects of any of these
factors on -cell compensation.
Ourobservationisconsistentwithre-
sults of several type 2 diabetes prevention
trials in which the best evidence for slow-
ing or arrest of declining -cell function
comes from interventions that either re-
duce body weight (21) or change the bi-
ology of fat (13,15,22). The role of
inﬂammation and adipokines in diabetes
prevention in these studies remains to be
determined. However, studies using aspi-
rin and salcylate (23,24) and IL-1 recep-
tor antagonist anakinra (25) indicate that
treatment of inﬂammation per se may
have beneﬁcial effects on glucose regula-
tion in pre-diabetic and diabetic humans.
In summary, we found a signiﬁcant
association between weight gain and de-
clining -cell compensation for insulin
resistance in Hispanic women at high risk
for type 2 diabetes. The effect was ex-
plained in part by changes in insulin re-
sistance and in part by changes in
circulating adiponectin and CRP. The re-
sults raise the possibility that increased
body fat contributes to declining -cell
function not only through insulin resis-
tance and increased demands on -cells
(13,15), but also through direct effects of
circulating adipose tissue peptides on
-cell replication and/or survival. Our
ﬁndings highlight the importance of re-
ducing body fat and/or its detrimental
metabolic effects to preserve pancreatic
-cell function and prevent or arrest the
progression to/of diabetes in high-risk
individuals.
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